Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
Level 5 - mechanism / opinion, no new human data
Preclinical animal models and in vitro human cell experiments with no clinical trial data
PubMed 17101732 · doi:10.1084/jem.20061104
What was done
Investigators evaluated phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) as modulators of antitumor immunity across several mouse tumor models and in combination with adoptive T-cell therapy. They also assessed sildenafil's effect on in vitro T-cell proliferation in peripheral blood mononuclear cells isolated from patients with multiple myeloma and head and neck cancer.
What was found
The abstract reports no quantitative values, confidence intervals, or p-values. Qualitatively, PDE5 inhibition delayed tumor progression in mice, downregulated arginase 1 and nitric oxide synthase-2 expression in CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs), and enhanced intratumoral T-cell infiltration and activation. Sildenafil improved adoptive T-cell therapy efficacy in mice and restored in vitro proliferation of human patient-derived T cells.
Why it matters
This study identifies a mechanism by which clinically available non-oncology drugs can disrupt tumor-induced immunosuppression by targeting MDSCs. It establishes a preclinical rationale for repurposing PDE5 inhibitors as adjuvants to cancer immunotherapy.
Limits
All findings are preclinical, derived from animal models and in vitro assays rather than human clinical trials. The abstract provides no sample sizes for animal cohorts or human blood donors, and reports no numerical effect sizes, dosing thresholds, or in vivo human clinical outcomes.
Cited by
- supports PDE5 inhibitor erectile dysfunction drugs can alter the immune system to shift from protecting cancer cells to attacking and killing them.